Market Access/ News/ News/ News/ Sales and Marketing FDA panel backs Ardelyx CKD drug, despite agency concerns Phil Taylor Ardelyx, chronic kidney disease, fda, hyperphosphatemia, Ibsrela, Xphozah 0 Comment While the FDA seems to remain sceptical about the clinical benefits of Ardelyx’s chronic kidney disease (CKD) therapy Share X FDA panel backs Ardelyx CKD drug, despite agency concerns https://pharmaphorum.com/news/fda-panel-backs-ardelyx-ckd-drug-despite-agency-concerns/
Ardelyx, chronic kidney disease, fda, hyperphosphatemia, Ibsrela, Xphozah
0 Comment
